EQUITY RESEARCH MEMO
QPharma
Generated 5/9/2026
Executive Summary
Conviction (model self-assessment)45/100
QPharma, established in 1994 and headquartered in Parsippany, NJ, is a privately held leader in patient engagement and compliance solutions for the life sciences industry. Through its best-in-class Titanium platform, the company helps pharmaceutical organizations improve medication adherence, drive patient support programs, and achieve regulatory compliance. With over two decades of experience and a workforce of 201–500 employees, QPharma serves as a trusted partner for brands seeking to navigate complex patient journeys and enhance outcomes. The company's integrated digital health and drug delivery focus positions it uniquely to address the growing demand for real-world evidence and patient-centric care.
Upcoming Catalysts (preview)
- Q2 2026Launch of next-generation Titanium platform with AI-driven analytics60% success
- H2 2026Strategic partnership with a top-20 global pharma company50% success
- Q4 2026Expansion into European market via new regulatory certifications40% success
Locked sections
- · Pipeline Analysis
- · Competitive Landscape
- · Catalyst Calendar (full 12-month)
- · Bull Case
- · Bear Case
- · Counterfactual Scenarios
- · Valuation Notes
- · SEC Filing Highlights
- · Insider Activity
- · Literature Watch
- · Patent Landscape
- · Mechanism Cluster Map
- · Audio Briefing (5 min)